Abbott Laboratories $ABT Stock Holdings Raised by HighTower Advisors LLC

HighTower Advisors LLC lifted its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 0.7% in the 3rd quarter, Holdings Channel.com reports. The firm owned 1,597,358 shares of the healthcare product maker’s stock after purchasing an additional 11,677 shares during the quarter. HighTower Advisors LLC’s holdings in Abbott Laboratories were worth $157,867,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of ABT. BlackRock Inc. boosted its position in Abbott Laboratories by 4.6% during the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after purchasing an additional 6,769,518 shares in the last quarter. State Street Corp grew its holdings in Abbott Laboratories by 1.7% in the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock valued at $7,343,246,000 after purchasing an additional 1,350,766 shares during the period. Bank of America Corp DE purchased a new stake in shares of Abbott Laboratories in the second quarter valued at approximately $1,603,607,000. Deutsche Bank AG increased its position in shares of Abbott Laboratories by 18.6% in the second quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker’s stock valued at $1,515,963,000 after buying an additional 2,614,965 shares in the last quarter. Finally, Legal & General Group Plc purchased a new stake in shares of Abbott Laboratories in the second quarter valued at approximately $1,082,524,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 2.6%

ABT stock opened at $104.64 on Wednesday. The company has a current ratio of 1.45, a quick ratio of 1.00 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $132.02. The stock has a market cap of $181.23 billion, a price-to-earnings ratio of 39.04, a PEG ratio of 1.88 and a beta of 0.54. The business’s 50-day moving average is $103.89 and its 200 day moving average is $101.74.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting the consensus estimate of $1.42. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The company had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. During the same period in the previous year, the business earned $1.30 EPS. Abbott Laboratories’s quarterly revenue was up 14.5% on a year-over-year basis. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, November 16th. Stockholders of record on Thursday, October 15th were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. Abbott Laboratories’s payout ratio is currently 94.03%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ABT shares. UBS Group reduced their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Weiss Ratings raised shares of Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, September 18th. Wells Fargo & Company boosted their price target on shares of Abbott Laboratories from $112.00 to $119.00 and gave the stock an “overweight” rating in a report on Thursday, October 22nd. Wall Street Zen upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, October 24th. Finally, Argus cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, October 27th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and an average price target of $118.32.

View Our Latest Stock Report on Abbott Laboratories

Insider Activity

In related news, EVP Mary Moreland sold 3,500 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total transaction of $406,000.00. Following the completion of the sale, the executive vice president directly owned 100,791 shares in the company, valued at approximately $11,691,756. The trade was a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Read More

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.